GBS
MCID: GLL022
MIFTS: 64

Guillain-Barre Syndrome (GBS)

Categories: Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Guillain-Barre Syndrome

MalaCards integrated aliases for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 12 54 26 38 56 44 45 15 17 74
Guillain-Barré Syndrome 77 54 26 55 3
Fisher Syndrome 26 55 38
Acute Inflammatory Demyelinating Polyneuropathy 54 74
Acute Inflammatory Polyneuropathy 54 26
Gbs 54 26
Acute Inflammatory Demyelinating Polyradiculoneuropathy 54
Acute Autoimmune Peripheral Neuropathy 54
Landry-Guillain-Barre-Strohl Syndrome 54
Acute Immune-Mediated Polyneuropathy 54
Acute Postinfectious Polyneuropathy 12
Guillain-Barré-Strohl Syndrome 54
Landry-Guillain-Barre Syndrome 26
Acute Inflammatory Neuropathy 54
Acute Infectious Polyneuritis 26
Acute Infective Polyneuritis 12
Post-Infectious Polyneuritis 12
Landry's Ascending Paralysis 54
Postinfectious Polyneuritis 12
Post-Infective Polyneuritis 54
Miller Fisher Syndrome 74
Infectious Neuronitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12842
MeSH 45 D020275
NCIt 51 C116345
SNOMED-CT 69 40956001
ICD10 34 G61.0

Summaries for Guillain-Barre Syndrome

MedlinePlus : 44 Guillain-Barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (PNS). The PNS nerves connect your brain and spinal cord with the rest of your body. Damage to these nerves makes it hard for them to transmit signals. As a result, your muscles have trouble responding to your brain. No one knows what causes the syndrome. Sometimes it is triggered by an infection, surgery, or a vaccination. The first symptom is usually weakness or a tingling feeling in your legs. The feeling can spread to your upper body. In severe cases, you become almost paralyzed. This is life-threatening. You might need a respirator to breathe. Symptoms usually worsen over a period of weeks and then stabilize. Guillain-Barre can be hard to diagnose. Possible tests include nerve tests and a spinal tap. Most people recover. Recovery can take a few weeks to a few years. Treatment can help symptoms, and may include medicines or a procedure called plasma exchange. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Guillain-Barre Syndrome, also known as guillain-barré syndrome, is related to miller fisher syndrome and peripheral nervous system disease, and has symptoms including seizures, tremor and back pain. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Allograft rejection and Human T-cell leukemia virus 1 infection. The drugs Immunologic Factors and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

Genetics Home Reference : 26 Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In Guillain-Barré syndrome, the immune response damages peripheral nerves, which are the nerves that connect the central nervous system (the brain and spinal cord) to the limbs and organs. Specifically, the immune response affects a particular part of peripheral nerves called axons, which are the extensions of nerve cells (neurons) that transmit nerve impulses. Guillain-Barré syndrome can affect the neurons that control muscle movement (motor neurons); the neurons that transmit sensory signals such as pain, temperature, and touch (sensory neurons); or both. As a result, affected individuals can experience muscle weakness or lose the ability to feel certain sensations.

NIH Rare Diseases : 54 Guillain-Barré syndrome (GBS) is a rare syndrome in which the body�??s immune system attacks part of the peripheral nervous system. The peripheral nervous system carries signals from the brain to the muscles. Symptoms of GBS include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all (paralysis). The exact cause of Guillain-Barré syndrome is unknown. In most cases, GBS occurs a few days or weeks after symptoms of a viral infection. In rare cases, GBS may run in families. A diagnosis of GBS is suspected when a person has symptoms suggestive of the syndrome. A variety of tests, including a spinal tap, may be completed to confirm the diagnosis. Treatment options may include plasma exchange (plasmapheresis) and immunoglobulin therapy. 

CDC : 3 Guillain-Barré syndrome (GBS) is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. While its cause is not fully understood, the syndrome often follows infection with a virus or bacteria. In the United States, an estimated 3,000 to 6,000 people develop GBS each year. Most people recover fully from GBS, but some have permanent nerve damage.

NINDS : 55 Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barré syndrome. It is characterized by abnormal muscle coordination, paralysis of the eye muscles, and absence of the tendon reflexes. Like Guillain-Barré syndrome, symptoms may be preceded by a viral illness. Additional symptoms include generalized muscle weakness and respiratory failure. The majority of individuals with Miller Fisher syndrome have a unique antibody that characterizes the disorder.

Wikipedia : 77 Guillain–Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the... more...

Related Diseases for Guillain-Barre Syndrome

Diseases in the Guillain-Barre Syndrome family:

Guillain-Barre Syndrome, Familial

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 miller fisher syndrome 33.8 HMGA2 TNF
2 peripheral nervous system disease 32.1 ALB MBP MPZ PMP22 TNF
3 polyneuropathy 30.9 MBP MPZ PMP22
4 pustulosis of palm and sole 30.9 TNF TNFRSF1B
5 demyelinating polyneuropathy 30.7 ALB HP PMP22
6 demyelinating disease 30.5 MBP TNF TNFRSF1A
7 optic neuritis 30.4 MBP MPZ TNF
8 viral hepatitis 30.3 ALB HLA-DQA1 TNF
9 toxoplasmosis 30.1 HLA-DQA1 HLA-DQB1 TNF
10 membranous nephropathy 30.1 ALB HLA-DQA1 TNF
11 neuritis 30.1 MBP MPZ PMP2 PMP22 TNF
12 leishmaniasis 30.1 HLA-DQA1 HLA-DQB1 TNF
13 multiple sclerosis 30.1 HLA-DQB1 MBP MPZ TNF TNFRSF1A
14 chronic inflammatory demyelinating polyradiculoneuropathy 30.1 ALB MPZ PMP22 TNFRSF1A
15 pelizaeus-merzbacher disease 30.1 MBP MPZ PMP22
16 polyradiculoneuropathy 29.9 ALB MBP MPZ PMP2 PMP22
17 charcot-marie-tooth disease 29.8 MBP MPZ PMP2 PMP22
18 systemic lupus erythematosus 29.7 ALB HLA-DQA1 HLA-DQB1 TNF TNFRSF1A TNFRSF1B
19 rheumatoid arthritis 29.6 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A TNFRSF1B
20 acute disseminated encephalomyelitis 29.3 HCRT HLA-DQA1 HLA-DQB1 MBP MPZ
21 guillain-barre syndrome, familial 12.8
22 kozlowski warren fisher syndrome 12.1
23 chronic inflammatory demyelinating polyneuropathy 11.8
24 dysautonomia 11.7
25 zika virus infection 11.7
26 chronic polyradiculoneuritis 11.4
27 lewis-sumner syndrome 11.4
28 neuropathy, hereditary sensory and autonomic, type iii 11.4
29 acute flaccid myelitis 11.4
30 facial diplegia with paresthesias 11.0
31 bickerstaff brainstem encephalitis 10.9
32 herpes simplex 10.5
33 hepatitis 10.5
34 influenza 10.5
35 mumps 10.5
36 acute pandysautonomia 10.5
37 acute sensory ataxic neuropathy 10.5
38 paraparetic variant of guillain-barré syndrome 10.5
39 acute pure sensory neuropathy 10.5
40 pharyngeal-cervical-brachial variant of guillain-barré syndrome 10.5
41 acute motor axonal neuropathy 10.5
42 acute motor and sensory axonal neuropathy 10.5
43 welander distal myopathy 10.4
44 charcot-marie-tooth hereditary neuropathy 10.4 MPZ PMP22
45 nephrotic syndrome 10.4
46 meningovascular neurosyphilis 10.4 ALB MBP
47 foot drop 10.4 MPZ PMP22
48 roussy-levy hereditary areflexic dystasia 10.4 MPZ PMP22
49 charcot-marie-tooth disease, demyelinating, type 1f 10.4 MPZ PMP22
50 respiratory failure 10.4

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:



Diseases related to Guillain-Barre Syndrome

Symptoms & Phenotypes for Guillain-Barre Syndrome

UMLS symptoms related to Guillain-Barre Syndrome:


seizures, tremor, back pain, ophthalmoplegia, pain, headache, syncope, chronic pain, sciatica, cerebellar ataxia, vertigo/dizziness, sleeplessness, neuralgia

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 HCRT HLA-DQB1 MBP MPZ PMP2 PMP22
2 homeostasis/metabolism MP:0005376 10.13 ALB DAAM2 HCRT HLA-DQB1 HP MBP
3 cellular MP:0005384 10.07 ALB HLA-DQB1 HP MBP MPZ PMP22
4 cardiovascular system MP:0005385 10.01 DAAM2 HCRT HLA-DQB1 HP TH TNF
5 liver/biliary system MP:0005370 9.8 ALB HLA-DQB1 HP TH TNF TNFRSF1A
6 muscle MP:0005369 9.76 ALB DAAM2 HCRT HLA-DQB1 PMP22 TNF
7 neoplasm MP:0002006 9.43 ALB HP TH TNF TNFRSF1A TNFRSF1B
8 nervous system MP:0003631 9.32 HCRT HLA-DQB1 MBP MPZ PMP2 PMP22

Drugs & Therapeutics for Guillain-Barre Syndrome

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
2 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3
Pembrolizumab Approved Phase 3 1374853-91-4
4 Immunoglobulins Phase 3,Phase 2,Not Applicable
5 Antibodies Phase 3,Phase 2,Not Applicable
6 Antineoplastic Agents, Immunological Phase 3
7
4-Aminopyridine Approved Phase 2 504-24-5 1727
8
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
9
Lactitol Investigational Phase 2 585-86-4, 585-88-6 493591
10 Complement System Proteins Phase 2
11 gamma-Globulins Phase 2,Not Applicable
12 Rho(D) Immune Globulin Phase 2,Not Applicable
13 Immunoglobulins, Intravenous Phase 2,Not Applicable
14 Pharmaceutical Solutions Phase 2,Not Applicable
15 Potassium Channel Blockers Phase 2
16 MF59 oil emulsion Phase 2
17 Anti-Inflammatory Agents Phase 2
18 glucocorticoids Phase 2
19 Antineoplastic Agents, Hormonal Phase 2
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
21 Hormones Phase 2
22 Hormone Antagonists Phase 2
23 Hemagglutinins Phase 2
24
Sodium Citrate Approved, Investigational Not Applicable 68-04-2
25
Infliximab Approved 170277-31-3
26
nivolumab Approved 946414-94-4
27
Thiamine Approved, Investigational, Nutraceutical, Vet_approved 59-43-8, 70-16-6 1130
28
Calcium Approved, Nutraceutical Not Applicable 7440-70-2 271
29
Citric Acid Approved, Nutraceutical, Vet_approved Not Applicable 77-92-9 311
30 Vitamin B Complex
31 Vitamins
32 Thiamin
33 Chelating Agents Not Applicable
34 Calcium, Dietary Not Applicable
35 Citrate Not Applicable
36 Anticoagulants Not Applicable
37 Antirheumatic Agents
38 Dermatologic Agents
39 Gastrointestinal Agents
40 Hemostatics Not Applicable
41 Coagulants Not Applicable
42 Immunoglobulin G
43 Autoantibodies

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
2 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
3 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
4 Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801 Completed NCT01604746 Phase 3
5 Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination Completed NCT01934140 Phase 3
6 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
7 A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered). Completed NCT03189745 Phase 3
8 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting NCT03486873 Phase 3 Standard of Care (SOC)
9 Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older Terminated NCT00976027 Phase 3
10 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
11 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Completed NCT02780570 Phase 2
12 Early Mechanical Ventilation for Guillain Barré Syndrome Completed NCT00167622 Phase 2
13 Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
14 JET-GBS - Japanese Eculizumab Trial for GBS Completed NCT02493725 Phase 2 Eculizumab;Placebo
15 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Completed NCT03174964 Phase 2 IVIg
16 Seasonal Flu Vaccine in Adult Transplant Recipients Completed NCT01258023 Phase 2
17 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
18 Sanofi H1N1 + TIV - Adults and Elderly Completed NCT00943878 Phase 2 Placebo
19 Novartis H1N1 Vaccine in Pregnant Women Completed NCT00992719 Phase 2
20 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women Completed NCT01173211 Phase 2
21 Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations Completed NCT00963157 Phase 2 AS03
22 H1N1 Vaccine at Two Dose Levels in HIV Positive Adults Completed NCT00992433 Phase 2
23 Sanofi Pasteur, TIV + H1N1, Pediatric Population Completed NCT00943202 Phase 2
24 H1N1 Vaccine in Pregnant Women Completed NCT00963430 Phase 2
25 Study of GLS-5700 in Dengue Virus Seropositive Adults Completed NCT02887482 Phase 1
26 Study of GLS-5700 in Healthy Volunteers Completed NCT02809443 Phase 1
27 A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS) Suspended NCT03773328 Phase 1
28 International Guillain-Barré Syndrome Outcome Study Unknown status NCT01582763
29 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
30 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
31 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
32 Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions. Unknown status NCT01516385
33 Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent Patients Unknown status NCT02164487
34 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858 Not Applicable
35 Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS) Completed NCT01306578 Not Applicable IVIG
36 Safety Study of GBS Following Menactra Meningococcal Vaccination Completed NCT00575653
37 Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome Completed NCT02883270 Not Applicable
38 Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome. Completed NCT01024088
39 Brain Computer Interface for Communication in ICU: a Feasibility Study Completed NCT01005524
40 Regional Citrate Anticoagulation in Plasma Exchange Treatment Completed NCT01370200 Not Applicable
41 Cervarix Long-term Safety Surveillance Completed NCT01498627
42 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
43 Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age Completed NCT01985997
44 Surveillance for Adverse Events Following Pandemic H1N1 Immunization Completed NCT01289418
45 Surveillance for Adverse Events Following Influenza Immunization Completed NCT01318876
46 Database Surveillance Safety Study of PENTACEL® Vaccine Completed NCT00804284
47 Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines Completed NCT02893878
48 Recovery of Visual Acuity in People With Vestibular Deficits Completed NCT00411216 Not Applicable
49 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
50 Neurologic Manifestations of the Arbovirus Infection in Colombia Recruiting NCT03206541

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: guillain-barre syndrome

Genetic Tests for Guillain-Barre Syndrome

Anatomical Context for Guillain-Barre Syndrome

MalaCards organs/tissues related to Guillain-Barre Syndrome:

42
Brain, Testes, Spinal Cord, Heart, Eye, T Cells, Skin

Publications for Guillain-Barre Syndrome

Articles related to Guillain-Barre Syndrome:

(show top 50) (show all 2260)
# Title Authors Year
1
Guillain Barré syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma. ( 30648445 )
2019
2
Zika Virus-Associated Aseptic Meningitis and Guillain-Barre Syndrome in a Traveler Returning from Latin America: a Case Report and Mini-Review. ( 30767073 )
2019
3
An overlapping case of Bickerstaff brainstem encephalitis and acute motor axonal neuropathy variant of Guillain-Barré syndrome associated with systemic lupus erythematosus. ( 30444497 )
2019
4
Bell's palsy and Guillain-Barré syndrome may be two ends of the same spectrum. ( 30908681 )
2019
5
Dry Beriberi Due to Thiamine Deficiency Associated with Peripheral Neuropathy and Wernicke's Encephalopathy Mimicking Guillain-Barré syndrome: A Case Report and Review of the Literature. ( 30862772 )
2019
6
Co-existent ulcerative colitis and Guillain-Barré syndrome: a case report and literature review. ( 30778832 )
2019
7
Intubation, tracheostomy, and decannulation in patients with Guillain-Barré-syndrome-does dysphagia matter? ( 30390307 )
2019
8
Concurrent Guillain-Barré syndrome, transverse myelitis and encephalitis post-Zika and multiple arboviral immunity. ( 30401491 )
2019
9
Systematic review of factors associated with the development of Guillain-Barré syndrome 2007-2017: what has changed? ( 30444562 )
2019
10
Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. ( 30536111 )
2019
11
Dysglycemia and Neurologic Outcome in Mechanically Ventilated Patients With Guillain-Barré Syndrome. ( 30585828 )
2019
12
Incidence study of Guillain-Barré syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. ( 30617450 )
2019
13
Fulminant Guillain-Barré syndrome in a patient with systemic lupus erythematosus. ( 30642853 )
2019
14
IVIg-induced plasmablasts in patients with Guillain-Barré syndrome. ( 30656191 )
2019
15
Do All Children with Guillain Barré Syndrome Need Immunotherapy? ( 30659495 )
2019
16
Ayurveda management of Guillain-Barre syndrome: A case report. ( 30661945 )
2019
17
Intravenous Immunoglobulin for Severe Protracted Pediatric Guillain-Barre Syndrome: Is Single Dose Adequate? ( 30692777 )
2019
18
A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method. ( 30696330 )
2019
19
Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants. ( 30705347 )
2019
20
Dynamic thiol-disulphide homeostasis in patients with Guillain-Barre Syndrome. ( 30730791 )
2019
21
Differentiation Between Guillain-Barré Syndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis-a Prospective Follow-up Study Using Ultrasound and Neurophysiological Measurements. ( 30756363 )
2019
22
Guillain-Barre Syndrome and Zika infection: Identifying leading producers, countries relative specialization, and collaboration. ( 30759205 )
2019
23
Assessing seasonal dynamics of Guillain-Barré syndrome with search engine query data. ( 30762168 )
2019
24
Efficient design and analysis of randomized controlled trials in rare neurological diseases: An example in Guillain-Barré syndrome. ( 30785890 )
2019
25
Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome. ( 30788172 )
2019
26
Outbreak of Guillain-Barre syndrome in Peru. ( 30788441 )
2019
27
Elevated resistin levels may regulate high mobility group box 1 expression in Guillain-Barré syndrome. ( 30826699 )
2019
28
Paralytic rabies: A Guillain-Barre Syndrome mimic. ( 30830154 )
2019
29
Risk factors for respiratory failure in Guillain-Barré syndrome in Bangladesh: a prospective study. ( 30847364 )
2019
30
Guillain-Barré syndrome as a complication of hypertensive basal ganglia haemorrhage. ( 30852075 )
2019
31
Antibodies to dengue, Zika, Campylobacter jejuni and gangliosides in Guillain-Barre syndrome. ( 30860160 )
2019
32
Virus-triggered spinal cord demyelination is followed by a peripheral neuropathy resembling features of Guillain-Barré Syndrome. ( 30872675 )
2019
33
Prevalence and outcomes of Guillain-Barré syndrome among pediatrics in Saudi Arabia: a 10-year retrospective study. ( 30880987 )
2019
34
Guillain-Barré syndrome in a patient of acute Hepatitis E virus infection associated with genotype 1: Case report and literature review. ( 30881857 )
2019
35
Guillain-Barré syndrome associated with Zika virus infection in Brazil: a cost-of-illness study. ( 30892628 )
2019
36
Guillain-Barre syndrome: a rare complication of leptospirosis and scrub typhus co-infection. ( 30895887 )
2019
37
Guillain-Barré Syndrome and Its Variants: Clinical Course and Prognostic Factors. ( 30911241 )
2019
38
Guillain-Barré syndrome with unilateral peripheral facial and bulbar palsy in a child: A case report. ( 30915222 )
2019
39
Case report: Guillain-Barre syndrome with pneumococcus - A new association in pediatrics. ( 29387550 )
2018
40
Post Vaccination Guillain Barre Syndrome: A Case Report. ( 29930889 )
2018
41
Motor Nerve Conduction Block Predicting Outcome of Guillain-Barre Syndrome. ( 29910770 )
2018
42
Epidemiology and Clinical Features of Guillain-Barre Syndrome in Isfahan, Iran. ( 29930927 )
2018
43
Guillain-Barre syndrome associated with hemorrhagic fever with renal syndrome in China: a case report. ( 29587642 )
2018
44
Characteristics, incidence and outcome of patients admitted to intensive care unit with Guillain-Barre syndrome in Australia and New Zealand. ( 29413724 )
2018
45
Guillain-Barre syndrome caused by hepatitis E infection: case report and literature review. ( 29357816 )
2018
46
Acute-onset Restless legs syndrome in acute neurological conditions-a prospective study on patients with the Guillain-Barre syndrome and acute stroke. ( 29359321 )
2018
47
Nivolumab-Associated Guillain-Barre Syndrome in a Patient With Non-Small-Cell Lung Cancer. ( 29889678 )
2018
48
Pulmonary adenocarcinoma associated with Guillain-Barré syndrome: A case report. ( 29794751 )
2018
49
Ischemic polyradiculoneuropathy with an aortic aneurysm masquerading Guillain-Barré syndrome. ( 30038123 )
2018
50
Guillain-Barré syndrome following bacterial meningitis: a case report and literature review. ( 30558576 )
2018

Variations for Guillain-Barre Syndrome

Expression for Guillain-Barre Syndrome

Search GEO for disease gene expression data for Guillain-Barre Syndrome.

Pathways for Guillain-Barre Syndrome

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A TNFRSF1B
2 12.12 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A
3
Show member pathways
11.94 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A
4
Show member pathways
11.91 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A TNFRSF1B
5 11.9 HLA-DQA1 HLA-DQB1 MPZ
6 11.81 HLA-DQA1 HLA-DQB1 TNF TNFRSF1A
7
Show member pathways
11.79 TNF TNFRSF1A TNFRSF1B
8 11.77 TNF TNFRSF1A TNFRSF1B
9 11.72 MBP MPZ PMP22
10 11.69 HLA-DQA1 HLA-DQB1 TNF
11 11.63 HLA-DQA1 HLA-DQB1 TNF
12
Show member pathways
11.5 TNF TNFRSF1A TNFRSF1B
13 11.45 TNF TNFRSF1A TNFRSF1B
14 11.31 TNF TNFRSF1A TNFRSF1B
15
Show member pathways
11.2 TNF TNFRSF1A TNFRSF1B
16 11.02 TNF TNFRSF1A TNFRSF1B
17 10.94 TNF TNFRSF1A
18 10.3 TNF TNFRSF1A TNFRSF1B

GO Terms for Guillain-Barre Syndrome

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II protein complex GO:0042613 9.26 HLA-DQA1 HLA-DQB1
2 myelin sheath GO:0043209 9.26 ALB MBP MPZ PMP2
3 compact myelin GO:0043218 9.16 MBP PMP22
4 tumor necrosis factor receptor superfamily complex GO:0002947 8.62 TNFRSF1A TNFRSF1B

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.84 HCRT MBP MPZ PMP22
2 immune response GO:0006955 9.83 HLA-DQA1 HLA-DQB1 MBP TNF TNFRSF1B
3 defense response GO:0006952 9.75 HP TNF TNFRSF1A
4 tumor necrosis factor-mediated signaling pathway GO:0033209 9.63 TNF TNFRSF1A TNFRSF1B
5 negative regulation of cardiac muscle hypertrophy GO:0010614 9.57 TNFRSF1A TNFRSF1B
6 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.56 TNF TNFRSF1B
7 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.55 HLA-DQA1 HLA-DQB1
8 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.54 TNF TNFRSF1A TNFRSF1B
9 positive regulation of ceramide biosynthetic process GO:2000304 9.52 TNF TNFRSF1A
10 response to salt stress GO:0009651 9.51 TH TNF
11 myelination GO:0042552 9.5 MBP MPZ PMP22
12 cellular response to nicotine GO:0071316 9.49 TH TNF
13 death-inducing signaling complex assembly GO:0071550 9.48 TNF TNFRSF1A
14 regulation of establishment of endothelial barrier GO:1903140 9.4 TNF TNFRSF1A
15 aortic valve development GO:0003176 9.26 TNFRSF1A TNFRSF1B
16 negative regulation of extracellular matrix constituent secretion GO:0003332 9.16 TNFRSF1A TNFRSF1B
17 positive regulation of apoptotic process involved in morphogenesis GO:1902339 8.96 TNFRSF1A TNFRSF1B
18 pulmonary valve development GO:0003177 8.62 TNFRSF1A TNFRSF1B

Molecular functions related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.16 HLA-DQA1 HLA-DQB1
2 tumor necrosis factor-activated receptor activity GO:0005031 8.96 TNFRSF1A TNFRSF1B
3 tumor necrosis factor binding GO:0043120 8.62 TNFRSF1A TNFRSF1B

Sources for Guillain-Barre Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....